Compass Therapeutics provides business update

Compass Therapeutics reported a business update. Development Pipeline Updates: CTX-009: Continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in BTC. Enrollment is expected to be completed by mid-year 2024; top line data are expected from this study in the second half of 2024. Enrollment of patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 as a monotherapy in patients with advanced, metastatic CRC, has been extended to first quarter 2024. Expect to report top-line data from this study by mid-year 2024. CTX-471: Continue to dose and follow patients in the Phase 1b monotherapy study of CTX-471 where five responses have been observed, all in patients who previously received checkpoint blocker. Phase 1b combination arm of CTX-471 and Merck’s anti-PD-1 therapy KEYTRUD in patients with select solid tumors is ongoing. The dose-escalation portion of the study has been fully enrolled and enrollment in the dose expansion cohorts has begun. CTX-8371: Following the FDA acceptance of the IND for CTX-8371, the first patient is expected to be dosed in the Phase 1 clinical trial in the first quarter of 2024.